Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Trial Profile

Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Suspended
Phase of Trial: Phase II

Latest Information Update: 11 May 2015

At a glance

  • Drugs OMS 824 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Sponsors Omeros Corporation
  • Most Recent Events

    • 11 May 2015 Omeros finalized the evaluation of data from nonclinical rat and non-human primate studies in its OMS824 program and submitted the package of nonclinical materials requested by the FDA, seeking to re-initiate its OMS824 Phase 2 Huntington's disease and schizophrenia programs. The company looks forward to re-activating enrollment in the OMS824 program in the near future.
    • 24 Oct 2014 Planned number of patients changed from 120 to 36, as reported by ClinicalTrials.gov.
    • 17 Oct 2014 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top